Healthcare Services

Non-Proliferative Diabetic Retinopathy Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-proliferative diabetic retinopathy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Non-Proliferative Diabetic Retinopathy Market?

The non-proliferative diabetic retinopathy market has witnessed substantial growth in recent years. It is anticipated to expand from $2.83 billion in 2025 to $3.06 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to the widespread occurrence of diabetes, insufficient understanding of retinal complications, a reliance on traditional laser treatments, infrequent use of intravitreal injections, and inadequate screening facilities.

The market for non-proliferative diabetic retinopathy is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $3.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.8%. Several factors are contributing to this projected growth, including the increasing occurrence of diabetic retinopathy, wider acceptance of anti-VEGF and steroid treatments, the proliferation of ophthalmology clinics and specialized centers, advancements in retinal imaging technologies, and enhanced patient education and early detection initiatives. Key trends anticipated during the forecast period encompass the increasing application of anti-VEGF therapy in npdr, greater utilization of intraocular steroid injections, the rising implementation of sophisticated laser surgery methods, wider adoption of vitrectomy procedures, and the progressing incorporation of AI-powered retinal imaging and diagnostic tools.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp

Which Drivers Are Supporting The Rise Of The Non-Proliferative Diabetic Retinopathy Market?

The expanding occurrence of diabetes is projected to fuel the expansion of the non-proliferative diabetic retinopathy market moving ahead. This condition is a persistent metabolic ailment marked by high blood glucose levels, resulting from either insufficient insulin production by the pancreas or the body’s cells developing resistance to insulin’s effects. Contributing factors to diabetes include inactive lifestyles, poor eating habits, and hereditary inclinations. Diabetes leads to non-proliferative diabetic retinopathy through damage to the retinal blood vessels, predominantly from extended periods of high blood glucose, which can cause vision problems and eventual blindness. As an illustration, the National Health Service (NHS), a UK government body, reported in June 2024 that in 2023, more than 549,000 new individuals in England were identified as being at risk of type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This figure shows a notable increase from 3,065,825 in 2022, indicating an almost 20% surge. Consequently, the growing incidence of diabetes is a key driver for the expansion of the non-proliferative diabetic retinopathy market.

What Segments Are Identified Within The Structure Of The Non-Proliferative Diabetic Retinopathy Market?

The non-proliferative diabetic retinopathy market covered in this report is segmented –

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy

2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)

2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

What Trends Are Projected To Support The Growth Of The Non-Proliferative Diabetic Retinopathy Market?

Leading companies in the non-proliferative diabetic retinopathy (NPDR) market are prioritizing the development of advanced clinical solutions, such as Phase 3 registrational trial enrollment, to enhance therapeutic validation, generate robust evidence, and support regulatory approval for emerging NPDR treatments. This type of enrollment involves the formal initiation and randomization of patients into a pivotal late-stage clinical trial, specifically designed to produce comprehensive efficacy and safety data essential for market authorization of a therapeutic intervention. For instance, in November 2025, Ocular Therapeutix, a US-based biopharmaceutical company specializing in retinal diseases, announced the first patient randomization in the HELIOS-3 Phase 3 registrational program assessing AXPAXLI (OTX-TKI) for NPDR. AXPAXLI is an investigational bioresorbable intravitreal hydrogel that contains axitinib, a tyrosine kinase inhibitor with anti-angiogenic activity, engineered to deliver sustained therapy with fewer injections. The HELIOS-3 trial, along with HELIOS-2, employs a novel ordinal =2-step Diabetic Retinopathy Severity Score (DRSS) improvement as the primary endpoint and includes patients with non-center-involved diabetic macular edema (non-CI-DME), thereby positioning AXPAXLI as a potentially transformative option for durable and effective NPDR management.

Which Key Market Players Are Investing In Expansion And Innovation Within The Non-Proliferative Diabetic Retinopathy Market?

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Which Regions Are Projected To Dominate The Non-Proliferative Diabetic Retinopathy Market In The Coming Years?

North America was the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Proliferative Diabetic Retinopathy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp

Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2026, By The Business Research Company

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Proliferative Diabetic Retinopathy Pdr Market Report 2026

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795